Top
Hunter’s Syndrome - Healing Genes
626
post-template-default,single,single-post,postid-626,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Hunter’s Syndrome

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

RGX-121 Gene Therapy in Patients With MPS II (Hunter Syndrome)

A Phase I/II Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of RGX-121 in Pediatric Subjects With MPS II (Hunter Syndrome)


Phase 1/2

DESCRIPTION:

Doctors are seeking male participants aged 4 months to 5 years old for a trial gene therapy to treat severe Hunter’s Syndrome. This gene therapy will be delivered directly to the brain, using a harmless virus as a way to transport a normal gene to replace the mutated gene that causes Hunter’s Syndrome.

Study participants will undergo a single dose of the trial therapy and be closely observed for the first 24 weeks post the treatment, with re-assessments at 48, 78, and 104 weeks. The researchers hope to see patients begin to normally produce the iduronate-2-sulfatase enzymes lacking due to their disease.


PATIENT MUST:

  • Be 4 months to 5 years old and male
  • Must meet any of the following criteria:
    • Has a documented diagnosis of MPS II and a has a neurocognitive testing score > 55 and ≤ 77 (Bayley or Kaufman), OR
    • Has a documented diagnosis of MPS II AND has a decline of ≥ 1 standard deviation on serial neurocognitive testing (Bayley or Kaufman) and a testing score > 55, OR
    • Has a relative diagnosed with severe MPS II who has the same IDS mutation as the subject AND in the opinion of a geneticist has inherited a severe form of MPS II

THE STUDY INVOLVES:

  1. Screening before the treatment
  2. Under anesthesia, a CT scan-guided injection to the spinal cord will deliver the treatment to the brain, inside the blood-brain barrier
  3. The patients will be observed closely for 24 weeks, then have visits at 48, 78, and 104 weeks.

LOCATIONS AND CONTACTS:

Trials will take place at the Children’s Hospital of Pittsburgh – UPMC: Program for Neurodevelopment in Rare Disorders. Map.

Contact: Jacob Wesley, Pharm D, MS  |  [email protected]  | 240-552-8181

Contact: Jodi Martin  |  412-692-6351  |  [email protected]

Contact: Dr. Maria Escolar |  [email protected]

 

SPONSOR INFORMATION:

Regenxbio Inc.

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03566043

 

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader